Industry & Policy News

[SAB Biotherapeutics] SAB Biotherapeutics announced that the US FDA has granted Fast Track designation for SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.

Merck and Eisai provided updates on two Phase III trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. [nan] Press...

[Loma Linda University School of Medicine] Loma Linda University (LLU) School of Medicine researchers received over $5.8 million in grants from the National Institutes of Health.

[Technical University of Munich] Hebrok works with pancreatic organoids in order to investigate diagnostic and therapeutic possibilities in pancreatic cancer and to enable cell replacement therapies for diabetes patients.

[The University of Queensland] Professor Ernst Wolvetang and his team at The University of Queensland's Australian Institute for Bioengineering and Nanotechnology have secured almost $1 million from the Medical Research Future Fund to test gene therapies for children with a specific type of Hereditary Spastic Paraplegia, using patient-derived organoids.

[Queen's University] Queen’s researchers are among five teams receiving $29 million from the Canadian Cancer Society to jumpstart innovative research and radically change the outcomes for six of the most common and deadly cancers.